On the stock market since 2012, it operates in the world of health and science. It has 1 employee. Now — the numbers.
This is an established company with proven profits.
Red columns mark years that ended in a loss.
If every debt were paid off today, $14.1M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 2,703,645% — still a thick cushion, though costs have been eating into it lately.
There is $14.4M in the vault; even if every debt were paid off, $14.1M would remain.
Over the last 12 months, company executives reported 8 buys and 2 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.0080. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, MAJI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MAJI is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.